Guard Therapeutics Intl (GUARD) Q4 2025 earnings summary

Executive summary

• Negative topline results from the phase 2b POINTER study led to the termination of the RMC-035 clinical program, marking a significant setback and prompting a strategic review, including potential merger or reverse acquisition options.

• The company initiated cost-saving measures, scaled down operations, and began winding down all RMC-035-related activities.

• After the reporting period, the company joined a European research consortium to evaluate GTX peptides for Alport's disease.

Financial highlights

• Net sales for both Q4 and the full year 2025 were 0 KSEK (0 KSEK in 2024).

• Net loss for Q4 was -16,330 KSEK (vs. -25,958 KSEK in Q4 2024); full-year net loss was -108,851 KSEK (vs. -96,066 KSEK in 2024).

• Earnings per share for the year were -6.04 SEK (-8.62 SEK in 2024).

• Cash and cash equivalents at year-end were 49,826 KSEK (54,186 KSEK in 2024).

• Operating loss for the year was -107,195 KSEK (-99,905 KSEK in 2024), mainly due to R&D expenses.

Outlook and guidance

• The strategic review is ongoing, with a focus on merger or reverse acquisition, expected to conclude in Q1 2026.

• Available cash is considered sufficient to fund operations through 2026.